About

<div class='kt-page'>

  <section class='kt-page-hero'>

    <div class='kt-wrap'>

      <span class='kt-eyebrow'>About Us</span>

      <h1>A quinolone specialist, built from a village chemical workshop</h1>

      <div class='kt-p'>Henan Kangtai Pharmaceutical traces its line to the Xingyang Sishui Fine Chemical Factory of 1985. Three decades later it is one of China&#8217;s most focused manufacturers of third-generation quinolone APIs and intermediates.</div>

    </div>

  </section>


  <div class='kt-wrap'>

    <h2>Who We Are</h2>

    <div class='kt-p'>Henan Kangtai Pharmaceutical Co., Ltd. is located at No.338 Kangtai Road, Sishui Town, Xingyang City &#8212; 40 kilometres west of Zhengzhou. The site covers 36,000 square metres and is a designated manufacturer of third-generation quinolone antibacterial APIs and intermediates.</div>

    <div class='kt-p'>The company employs 98 people, including 21 technical staff. It holds import and export rights granted in January 2000 and more than CNY 40 million in fixed assets. Products are sold across China and exported to more than 30 countries and regions.</div>

    <div class='kt-p'>The wider group history runs deeper: the original factory was established in 1985, the Henan Kangtai Pharmaceutical Group was formed in 1993, and the group brought together the Henan Province Fine Chemical Factory, the Xingyang Chemical Synthesis Research Institute and the Xingyang Kangtai Pharmaceutical Factory.</div>


    <h2>What We Make</h2>

    <div class='kt-p'>The portfolio is deliberately narrow and deep: quinolone APIs, the intermediates that feed them, and the fine chemicals that start the chain.</div>

    <ul class='kt-check'>

      <li><b>APIs</b> &#8212; norfloxacin, fleroxacin, gatifloxacin mesylate, pefloxacin mesylate, lomefloxacin hydrochloride and norfloxacin hydrochloride</li>

      <li><b>Veterinary and feed additives</b> &#8212; norfloxacin hydrochloride, nicotinate and lactate</li>

      <li><b>Intermediates</b> &#8212; the ethyl, piperazinyl and chlorofluoro quinolone carboxylic acid chain for norfloxacin</li>

      <li><b>Fine chemicals</b> &#8212; 3-chloro-4-fluoroaniline and diethyl ethoxymethylenemalonate (EMME)</li>

    </ul>


    <h2>Milestones</h2>

    <div class='kt-table-wrap'>

      <table class='kt-table'>

        <thead><tr><th>Year</th><th>Milestone</th></tr></thead>

        <tbody>

          <tr><td>1985</td><td>Xingyang Sishui Fine Chemical Factory established &#8212; the origin of today&#8217;s plant</td></tr>

          <tr><td>1993</td><td>Henan Kangtai Pharmaceutical Group formed; chemical synthesis, research and manufacturing entities combined</td></tr>

          <tr><td>2000</td><td>Independent import and export rights granted (28 January 2000)</td></tr>

          <tr><td>2005</td><td>Gatifloxacin mesylate developed as a national class-1 new drug on a domestic route</td></tr>

          <tr><td>2022</td><td>Certified National High-tech Enterprise; recognised as a Zhengzhou specialised-precise-special-new SME</td></tr>

          <tr><td>2023</td><td>Rated Excellent Private Enterprise of Xingyang City</td></tr>

        </tbody>

      </table>

    </div>


    <h2>Research and Development</h2>

    <div class='kt-p'>The Xingyang Chemical Synthesis Research Institute is the company&#8217;s dedicated R and D arm, responsible for product quality testing, new process development and the upgrade of existing production routes. It employs 23 people, five of them with senior titles.</div>

    <div class='kt-p'>The institute operates five conventional synthesis laboratories, a standard laboratory, a quality inspection centre equipped with HPLC and gas chromatography, and a pilot synthesis workshop of roughly 2,000 square metres. It maintains long-standing technical cooperation with the Chinese Academy of Medical Sciences, the Chinese Academy of Military Medical Sciences, China Pharmaceutical University and Zhengzhou University of Technology.</div>

    <div class='kt-p'>Work at the institute has covered fluorochlorobenzeneamine, trifluoronitrobenzene, tetrafluorobenzoic acid and the norfloxacin chain, taking each from laboratory route to industrial production.</div>


    <h2>Quality and Compliance</h2>

    <div class='kt-p'>The norfloxacin workshop was rebuilt to Good Manufacturing Practice requirements and certified by the Henan Provincial Food and Drug Administration. The company also holds the GMP certificate and the Written Confirmation (WC) required for active substances exported to the European Union.</div>

    <div class='kt-p'>Specifications are written to the pharmacopoeia the customer needs &#8212; USP, CP, EP, IP, JP or BP &#8212; and every batch ships with a certificate of analysis traceable to its production record.</div>


    <h2>Social Responsibility</h2>

    <div class='kt-p'>Kangtai takes part in local philanthropic and community programmes, and the plant&#8217;s environmental systems &#8212; wastewater treatment, waste-gas handling and solvent recovery &#8212; are designed into the process rather than added afterwards. The company has been recognised for environmental governance within Henan Province.</div>


    <div class='kt-cta' style='margin-top:56px'>

      <h2>Want the Full Company Profile?</h2>

      <div class='kt-p'>Ask for our company profile, product catalogue and GMP certificates &#8212; we send them as PDF by email.</div>

      <a class='kt-btn kt-btn-red' href='/p/contact.html'>Request Documents</a>

    </div>

  </div>

</div>


Comments

Post a Comment

Popular posts from this blog

Pharmaceutical supplier qualification for GMP audits

Batch-by-batch incoming testing does not make your facility audit-proof. Regulators routinely trace quality failures back to supplier controls rather than your own laboratory. The safeguard is pharmaceutical supplier qualification, not the volume of in-house tests you run. The real exposure sits in how you qualify vendors and verify their Certificates of Analysis before materials reach the production line. Why pharmaceutical supplier qualification is what auditors probe first Plenty of quality and procurement teams walk into overseas inspections quietly confident. The main production area, the water system, and the HPLC room look airtight. Raw materials and packaging arrive, get tested lot by lot, and pass before release. Surely no inspector can follow that trail all the way back to a supplier’s plant. That assumption underrates how far an FDA, PMDA, or EU auditor will dig. After four FDA on-site inspections plus PMDA, EU, and multiple multinational audits, the pattern is consistent. S...
Read more

Pharmaceutical material management: GMP receipt to release

Pharmaceutical material management controls how raw materials, excipients, packaging and biological substrates are received, tested, stored and released from R&D to commercial manufacture. It ties quality standards, supplier qualification, warehouse environmental control and retention obligations into one traceable framework. Plain and operational. Every lot that enters a product must be accounted for, with status, result and decision recorded at each step. Background and problem Pharmaceutical material management starts before the drug substance is made. It starts with the material. A finished batch is only as good as the materials that went into it. Regulators treat pharmaceutical material control as a core GMP obligation. When material management is weak, the consequences surface downstream: failed release tests, stability drift, product recalls, and warning letters from the national drug regulator. The difficulty is not one rule. It is the number of interfaces. A material moves...
Read more

Mutant prevention concentration: MPC/MIC ratios and dosing

Mutant prevention concentration is the drug level that blocks growth of first-step resistant mutants. Its distance from the MIC sets the width of the mutant selection window. Across a 100-isolate Gram-negative panel, median MPC/MIC ratios ran from 4 to 16 depending on the molecule. That spread has direct consequences for how a fluoroquinolone such as norfloxacin gets dosed. The numbers below come from a hospital isolate collection and are used here only as class-level read-across. The pharmacology of the selection window does not change with the host species. What changes is the achievable exposure, and that is where a veterinary formulator or a prescribing veterinarian has to do the arithmetic. Why the selection window matters more than the MIC Routine susceptibility testing reports one number: the MIC, the lowest concentration that stops visible growth of the bulk population. That number describes the majority. It says nothing about the small subpopulation already carrying a first-st...
Read more